NCT02691052View on ClinicalTrials.gov

Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program

CompletedOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions

Metastatic Pancreatic Cancer

Interventions

OTHER

Quality of Life questionnaire

EORTC QLQ-C30 questionnaire

Trial Locations (1)

60488

Krankenhaus Nordwest gGmbH - Institute of Clinical Cancer Research, Frankfurt

All Listed Sponsors

collaborator

Trium Analysis Online GmbH

INDUSTRY

collaborator

mca Berlin

UNKNOWN

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER

NCT02691052 - Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program | Biotech Hunter | Biotech Hunter